In a move to serve customers with ready-to-use solutions for organ-on-a-chip model development and analysis, MIMETAS and Molecular Devices will combine marketing efforts on the OrganoPlate® organ-on-a-chip platform and ImageXpress® Micro Confocal high-content imaging systems.
In collaboration with Biogen, Abbvie and Janssen, academic partners and SMEs, MIMETAS will develop neurovascular organs-on-chips models consisting of co-cultures of neurons, astrocytes and endothelial cells that will be relevant to investigate the role APOE in AD development.
MIMETAS is now a member of the HollandBIO community
MIMETAS welcomes André Hoekema and Bart Bergstein as members of the board. Dr. Hoekema is Senior Vice President Corporate Development of Galapagos since March 2005. He joined Galapagos from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe.
Mimetas has received 1.6 million USD funding for development of an organ-on-a-chip model for neurotoxicity. The aim of the project is to improve existing neurotoxicity tests and to reduce experimentation on animals.
MIMETAS receives EFRO grant for feasibility study
MIMETAS and the IRAS receive funding from GlaxoSmithKline, BASF, Sanofi, Abbvie and NC3Rs for a proof-of-concept study to develop human-relevant 3D cell cultures for in vitro approaches to screening for neurotoxicity and seizure likelihood.
MIMETAS B.V. announces that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology.
MIMETAS, in a consortium with Radboudumc and FHNW, has received 1.6 million USD funding for development of a kidney-on-a-chip for toxicological applications. A panel of experts from GlaxoSmithKline, Pfizer, Roche, NC3Rs and renowned academic institutions selected MIMETAS’ solution from a strong line-up of competing technologies.